Topical immunotherapy with diphencyprone for cutaneous metastatic melanoma

Phase 1

Completed

• Conditions: Melanoma metastatic and/or locally recurrent to skin; Cancer - Malignant melanoma

• Registration Number: ACTRN12609000475246
• Lead Sponsor: Royal Prince Alfred Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2009-06-17
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Melanoma locally recurrent or metastatic to skin

Exclusion Criteria

Pregnancy or lactation
Severe uncontrolled eczema
Previous type I hypersensitivity to diphencyprone
Primary melanoma

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Clinical clearance of cutaneous metastases (ie, active cutaneous lesions are no longer visible or palpable)[1, 3, 6, 12 and 24 months following development of contact hypersensitivity response to diphencyprone]

Secondary Outcome Measures

Name	Time	Method
Histological clearance of cutaneous metastases (S100 stain after melanin bleaching on biopsy taken from treated area)[1, 3, 6, 12 and 24 months following development of contact hypersensitivity response to diphencyprone]